Skip to content

US · ENSC · BIOTECHNOLOGY

Ensysce Biosciences, Inc. (ENSC) intrinsic value and stock valuation

$0.36as of 2026-11-21 · Mkt cap 4.83M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ensysce Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values ENSC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ENSC’s statements →

Ensysce Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology La Jolla, CA 92037 ensysce.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$5.07M+5.2% 5y CAGRd
20172025
Net income
-$-10.18M
20172025
Free cash flow
-$-7.81T
20172025
Total equity
$2.88M
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$5.07M$5.21M$2.23M$2.52M$3.53M
Operating income-$-10.24M-$-6.73M-$-10.72M-$-24.22M-$-19.87M
Net income-$-10.18M-$-7.99M-$-10.61M-$-24.17M-$-29.08M
EPSd-$-398.12K-$-4.57M-$-4.69M-$-134.28M-$-363.5M
Operating cash flow-$-7.81T-$-7.5T-$-10.78M-$-17.89M-$-8.24M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-7.81T-$-7.5T-$-10.78M-$-17.89M-$-8.24M
Total assets$7.45M$5.6M$2.71M$5.89M$16.4M
Total debt$306.7B$300K$850K$4.43M$17.2M
Net debt$306.7B-$-3.2M-$-270K$1.29M$4.95M
Total equity$2.88M$3.38M-$-650K-$-4.03M-$-8.16M
Cash and short-term investments$4.31M$3.5M$1.12M$3.15M$12.3M
Income statement
20252024202320222021
Revenue$5.07M$5.21M$2.23M$2.52M$3.53M
Cost of revenue$10.4M$7.22M$7.59M$19.8M$0.00
Gross profit-$-5.31M-$-2.01M-$-5.36M-$-17.31M$3.53M
Research and development expenses$10.4M$7.22M$7.59M$19.8M$4.69M
Selling, general and administrative expenses$4.93M$4.72M$5.36M$6.91M$18.7M
Other expenses-$-10.38M-$-7.22M-$-7.59M-$-19.84M-$-3.53M
Operating expenses$4.93M$4.72M$5.36M$6.91M$23.4M
Cost and expenses$15.3M$11.9M$13M$26.8M$23.4M
Interest income$0.00$0.00$0.00$1.25M$3.21M
Interest expense$20K$1.29M$350K$110K$1.29M
Depreciation and amortization$10K$0.00$0.00$0.00$0.00
Ebitda-$-10.15M-$-6.73M-$-10.72M-$-24.22M-$-25.93M
Operating income-$-10.24M-$-6.73M-$-10.72M-$-24.22M-$-19.87M
Total other income/expenses, net$60K-$-1.26M$90K$10K-$-9.28M
Income before tax-$-10.18M-$-7.99M-$-10.63M-$-24.21M-$-29.15M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-10.18M-$-7.99M-$-10.61M-$-24.17M-$-29.08M
Weighted average shares outstanding$2.56M$1.75M$2.26M$180K$80K
Weighted average diluted shares outstanding$25.6M$1.75M$2.26M$180K$80K
Balance sheet
20252024202320222021
Cash and short-term investments$4.31M$3.5M$1.12M$3.15M$12.3M
Net receivables$420K$120K$100K$280K$440K
Inventory$0.00$0.00$0.00$0.00-$-440K
Total current assets$7.24M$5.34M$2.29M$5.3M$15.7M
Property, plant and equipment, net$124.1B$0.00$0.00$0.00$24.7B
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$210K$250K$420K$590K$750K
Total assets$7.45M$5.6M$2.71M$5.89M$16.4M
Accounts payable$3.27M$1.36M$1.94M$2.94M$300K
Short-term debt$306.7B$300K$850K$4.29M$12.8M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.57M$2.21M$3.33M$9.46M$16.5M
Long-term debt$0.00$0.00$0.00$140K$4.44M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$10K$30K$450K$8.09M
Capital lease obligations$0.00$0.00$0.00$30K$20K
Total liabilities$4.57M$2.22M$3.36M$9.91M$24.6M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-139.72M-$-129.54M-$-121.56M-$-110.93M-$-85.85M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$2.88M$3.38M-$-650K-$-4.03M-$-8.16M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$306.7B$300K$850K$4.43M$17.2M
Net debt$306.7B-$-3.2M-$-270K$1.29M$4.95M
Cash flow statement
20252024202320222021
Net income-$-10.18T-$-7.99M-$-10.63M-$-24.21M-$-29.15M
Depreciation and amortization$6.53B$0.00$0.00$0.00$0.00
Stock-based compensation$668.7B$110.7B$880K$1.07M$120K
Change in working capital$1.52M-$-850K-$-950K$5.48M-$-1.3M
Accounts receivable-$-300K-$-30K$180K$160K-$-440K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.82M-$-580K-$-1.23M$2.64M-$-1.42M
Net cash provided by operating activities-$-7.81T-$-7.5T-$-10.78M-$-17.89M-$-8.24M
Investments in property, plant and equipment-$-120K$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-123.64B$0.00$0.00$0.00$0.00
Common stock issued$5.87M$1.67M$9.05M$3.78M$6.63M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-290M$0.00$0.00$0.00
Net cash used for financing activities$8.74T$9.88T$8.76M$8.77M$20.3M
Net change in cash$808.3B$2.38T-$-2.02M-$-9.12M$12.1M
Cash at end of period$4.31T$3.5T$1.12M$3.15M$12.3M
Operating cash flow-$-7.81T-$-7.5T-$-10.78M-$-17.89M-$-8.24M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-7.81T-$-7.5T-$-10.78M-$-17.89M-$-8.24M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ensysce Biosciences, Inc.

        Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

        CEO
        D. Lynn Kirkpatrick
        Employees
        10
        Beta
        0.90

        Explore

        Frequently asked questions

        What is the intrinsic value of Ensysce Biosciences, Inc. (ENSC)?

        InvestorsCraft does not currently publish an intrinsic value for ENSC. How the IC value is calculated.

        Is ENSC undervalued?

        InvestorsCraft does not publish an undervaluation signal for ENSC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.